- Home
- Publications
- Publication Search
- Publication Details
Title
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-01-09
DOI
10.3389/fonc.2018.00557
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
- (2018) S Novello et al. ANNALS OF ONCOLOGY
- Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
- (2018) Jianya Zhou et al. BMC CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- (2018) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK -positive non-small-cell lung cancer
- (2018) Makoto Nishio et al. LUNG CANCER
- Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
- (2018) S Gadgeel et al. ANNALS OF ONCOLOGY
- The Morphological and Molecular Diagnosis of Lung Cancer
- (2018) Iver Petersen Deutsches Arzteblatt International
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
- (2017) Michaël Duruisseaux et al. Oncotarget
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
- (2016) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
- (2016) Daniel Shao-Weng Tan et al. Journal of Thoracic Oncology
- Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- (2016) Scott N Gettinger et al. LANCET ONCOLOGY
- Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
- (2016) Tatsuya Yoshida et al. LUNG CANCER
- Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib inALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
- (2016) Shaohua Cui et al. Cancer Medicine
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden
- (2015) Annie Guérin et al. JOURNAL OF MEDICAL ECONOMICS
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
- (2012) Luis Paz-Ares et al. LANCET ONCOLOGY
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started